Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Teva, Sun Settle Patent Case for $2.15B

June 12, 2013 9:39 am | News | Comments

Two generic drugmakers will pay $2.15 billion to Pfizer and Takeda Pharmaceutical to settle a patent fight over the heartburn treatment Protonix. Teva Pharmaceutical Industries will pay $1.6 billion, while Sun Pharmaceutical Industries will pay $550 million.

TOPICS:

PDL Claims Shortchanging by Genentech

June 11, 2013 6:17 pm | News | Comments

PDL BioPharma Inc. wants take Roche's Genentech business to arbitration over a royalty payment dispute. PDL said Genentech has underpaid royalties since at least 2007, and it wants to have Genentech's books and records inspected to determine if payments were accurate.

TOPICS:

GSK Fires Researcher Over Data

June 11, 2013 5:22 pm | News | Comments

GlaxoSmithKline has dismissed one employee and a second resigned in the wake of a scandal over misrepresented data in a research paper published in 2010. The company says its investigation of recent allegations of questionable data has established that some information in the paper had been misrepresented.

TOPICS:
Advertisement

Better Development of Biosimilars

June 11, 2013 12:03 pm | by Savanna Steele, PharmD, Clinical Scientist; Song Wang, PhD, Associate Statistical Science Director; Brian Healey, PharmD, Associate Director; Dirk Reitsma, MD, Vice President; PPD, Wilmington, N.C. | Articles | Comments

In order to add assurance that the biosimilar candidate is as similar to the originator as possible, multiple tests should be used to assess similar qualities, an approach termed as “orthogonal” in the U.S. Food and Drug Administration draft biosimilar guidelines.

TOPICS:

Mass Spec Maturing in the Age of Proteomics

June 11, 2013 11:45 am | by Neil Canavan, Contributing Editor | Articles | Comments

Biomarkers are the order of the day—an endogenous signal flare that’s fired, perhaps even before actual disease onset, warning of impending illness. The problem for the clinician, and way before that, the researcher at the bench is how do you detect that tiny, diagnostically incandescent signal.

Questcor to Pay $135M for Synacthen

June 11, 2013 10:45 am | News | Comments

Questcor Pharmaceuticals Inc. said it will pay at least $135 million to buy an autoimmune and inflammatory disease drug made by Novartis AG. Questcor said it will pay $60 million upfront for Synacthen and Synacthen Depot, which are approved in about 40 countries as a treatment for a variety of illnesses.

TOPICS:

BMS Exec Admits Insider Trading

June 10, 2013 4:43 pm | News | Comments

Federal prosecutors in New Jersey say a former executive for Bristol-Myers Squibb has admitted using his high-level position and access to nonpublic information to make about $310,000 from insider trades. Robert Ramnarine has pleaded guilty to securities fraud.

TOPICS:

Vitaros Approved in 10 Countries

June 10, 2013 12:45 pm | News | Comments

Apricus Biosciences Inc. said that its impotence drug Vitaros has been approved in 10 European countries. The company said Vitaros is now approved in the Netherlands, Germany, France, Italy, and the U.K., among other countries, for the treatment of erectile dysfunction.

TOPICS:
Advertisement

Elan Rejects New Royalty Bid

June 10, 2013 11:12 am | News | Comments

The board of directors of the Irish drugmaker Elan Corp. PLC on Monday rejected an increased offer from Royalty Pharma and says it has received unsolicited interest from other parties it didn't name. Royalty's latest offer last week was for $13 per share plus up to $2.50 per share in payments based on performance milestones.

TOPICS:

FDA Finds More Tainted Steroids

June 10, 2013 11:08 am | News | Comments

Federal health officials say they have found bacteria and fungus in drug vials from a Tennessee specialty pharmacy that recalled all of its injectable medicines last month. The Food and Drug Administration said in an online posting that it identified the growths in two unopened vials of a steroid injection distributed by the Main Street Family Pharmacy, a compounding pharmacy in Newbern, Tenn.

TOPICS:

AstraZeneca in $560M Deal for Pearl

June 10, 2013 7:48 am | News | Comments

British drugmaker AstraZeneca PLC says it is to acquire Pearl Therapeutics Inc., a Redwood-City, California-based company involved in therapies for asthma and chronic obstructive pulmonary disease for at least $560 million. The deal could involve further payments of up to $590 million if if sales and drug development targets are met.

TOPICS:

Leukemia Pathway Discovery May Yield New Treatments

June 7, 2013 12:32 pm | News | Comments

Through genetic engineering of laboratory models, researchers have uncovered a vulnerability in the way cancer cells diverge from normal regenerating cells that may help treat children with leukemia. The researchers are trying to understand the key pathways that distinguish how a normal blood cell grows and divides compared to the altered growth that occurs in leukemia.

TOPICS:

Eylea Meets New Study Goal

June 7, 2013 12:14 pm | News | Comments

Regeneron Pharmaceuticals Inc. and Bayer HealthCare said that their eye drug Eylea met its main goal in a new late-stage clinical trial. The companies said Eylea was more effective than a sham injection in treating a condition called myopic choroidal neovascularization, a retina disease that affects people who are severely myopic.

TOPICS:

Belviq Gets US Launch Date

June 7, 2013 12:03 pm | by Matthew Perrone | News | Comments

Arena Pharmaceuticals says its weight loss drug Belviq will be available to U.S. patients beginning next week, nearly a year after the drug was officially approved by federal regulators. The Food and Drug Administration approved Belviq last June for adults who are obese or who are overweight and have at least one serious medical condition, such as diabetes or high cholesterol.

TOPICS:

Panel Favors Avandia Changes

June 6, 2013 5:44 pm | by Matthew Perrone | News | Comments

Federal health experts are recommending changes to safety restrictions on former blockbuster diabetes pill Avandia, in light of a new analysis suggesting that the drug may not increase the risk of heart attack as previously believed. A majority of Food and Drug Administration advisers voted to modify or remove measures that currently limit patient access to GlaxoSmithKline's Avandia.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading